5,6,7,8-四氢-5,5,8,8-四甲基萘-2-羧酰肼 | 1022171-49-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5,6,7,8-四氢-5,5,8,8-四甲基萘-2-羧酰肼
• 英文名称: 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxylic hydrazide
• 英文别名: 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbohydrazide；5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbohydrazide
• CAS: 1022171-49-8
• 化学式: C₁₅H₂₂N₂O
• 分子量: 246.352
• InChiKey: OSOQSDLICFOEAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢-5,5,8,8-四甲基萘-2-羧酰肼 、 4-硝基苯基甲基异硫氰酸酯 在 氧化汞(II)红 silica gel 、 正庚烷 、 ethyl acetate heptane 作用下， 以 乙醇 为溶剂， 反应 0.75h， 以produces the expected compound in the form of a white powder (540 mg; 66% yield)的产率得到N-(4-nitrobenzyl)-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,4-oxadiazol-2-amine
  参考文献：
  名称：

  PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT

  摘要：

  本发明涉及一种新的苯基衍生物，展现出对某些亚型的大麻素受体具有良好的亲和力，尤其是CB2受体。这些衍生物在治疗某些病理情况和疾病的方法中具有特别的兴趣，其中一个或多个大麻素受体参与其中。本发明还涉及含有这些新的苯基衍生物的药物组合物以及其制备和使用的方法。

  公开号：

  US20100056507A1
• 作为产物：
  描述：

  1,1,4,4-Tetramethyl-1,2,3,4-tetrahydro-naphthalincarbonsaeure-6-methylester 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以87%的产率得到5,6,7,8-四氢-5,5,8,8-四甲基萘-2-羧酰肼
  参考文献：
  名称：

  PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT

  摘要：

  本发明涉及新的苯基衍生物，具有良好的亲和力，特别是对CB2受体的某些亚型。这些衍生物在治疗涉及一个或多个大麻素受体的病理条件和疾病的方法中具有特殊的兴趣。本发明还涉及含有这些新的苯基衍生物的药物组合物，以及其制备和使用方法。

  公开号：

  US20100056507A1

文献信息

• INHIBITORS OF SPHINGOSINE KINASE
  申请人：Stieber Frank

  公开号：US20120252815A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , M 1 , M 2 , M 3 , Y 1 , Y 2 , V, W, n, m and o have the gleanings given herein, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

  本发明涉及化合物的结构式(I)，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、M1、M2、M3、Y1、Y2、V、W、n、m和o具有此处所述的含义，以及其生理上可接受的盐、衍生物、前药、溶剂化合物、互变异构体和立体异构体，包括所有比例的混合物，用于治疗受Sph激酶1抑制影响的疾病。
• Diaryl-substituted pyrazole compounds and drugs and cosmetics obtained
  申请人：BASF Aktiengesellschaft

  公开号：US05206242A1

  公开（公告）日：1993-04-27

  Compounds of formula I ##STR1## where R.sup.1 and R.sup.2 are each hydrogen or methyl, A is en ethylene or methylene radical which is unsubstituted or substituted by methyl, hydroxyl or oxo, L is a saturated or unsaturated five-membered or six-membered heterocyclic structure which is unsubstituted or substituted by hydroxyl, mercapto, C.sub.1 -C.sub.6 -alkyl, or C.sub.1 -C.sub.4 -alkanoyl and has from 1 to 3 heteroatoms from the group consisting of N, O and S, the second and third heteroatoms being a nitrogen atom, R.sup.3 is hydrogen, a hydroxy or C.sub.1 -C.sub.6 -alkoxy group, R.sup.4 is hydrogen, C.sub.1 -C.sub.4 -alkyl, halogen or methoxy, R.sup.5 is hydrogen or methoxy or tert-butyl, R.sup.6 is hydrogen, methyl, nitrile or a C.sub.2 -C.sub.10 -ketal group or the radical --CHR.sup.7 OR.sup.8 --CHR.sup.7 --NR.sup.9 R.sup.10, --COR.sup.11, --SR.sup.12, ##STR2## in which R.sup.7 is hydrogen or C.sub.1 -C.sub.4 -alkyl, R.sup.8 is hydrogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.20 -alkanoyl or is benzoyl which is unsubstituted or substituted by methoxy, nitro, methyl or chlorine, R.sup.9 and R.sup.10 are each hydrogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.6 -alkanoyl or are each benzoyl which is unsubstituted or substituted as for R.sup.8, or R.sup.9 and R.sup.10, together with the nitrogen atom to which they are bonded, form a saturated, 5-membered or 6-membered heterocyclic radical which may contain oxygen as the second heteroatom, R.sup.11 is hydrogen, C.sub.1 -C.sub.4 -alkyl, --OR.sup.13 or --NR.sup.14 R.sup.15, where R.sup.13 is hydrogen, unsubstituted or hydroxyl-substituted C.sub.1 -C.sub.6 -alkyl, aryl or aralkyl which is unsubstituted or substituted by chlorine, bromine, methyl, methoxy or nitro, substitution in the case of the aralkyl group being in the aryl moiety, and where R.sup.14 and R.sup.15 are each hydrogen, unsubstituted or hydroxyl-substituted C.sub.1 -C.sub.6 -alkyl or an aralkyl or aryl group which is unsubstituted or substituted as for R.sup.13, or R.sup.14 and R.sup.15, together with the nitrogen atom to which they are bonded, form a heterocyclic radical as defined above for R.sup.9 and R.sup.10, and R.sup.12 is C.sub.1 -C.sub.4 -alkyl, and compounds of formula Ia ##STR3## where R.sup.3, R.sup.4, R.sup.6 and L have the abovementioned meanings and R.sup.17 is hydrogen or hydroxyl, and their physiologically tolerated salts, processes for their preparation and drugs and cosmetics prepared therefrom.

  式I的化合物 ##STR1## 其中R.sup.1和R.sup.2分别为氢或甲基，A是未取代或取代为甲基，羟基或氧代的乙烯或亚甲基基团，L是未取代或取代为羟基，巯基，C.sub.1-C.sub.6-烷基或C.sub.1-C.sub.4-酰基的饱和或不饱和的五元或六元杂环结构，并且其中有1至3个来自N，O和S的杂原子，第二和第三个杂原子为氮原子，R.sup.3为氢，羟基或C.sub.1-C.sub.6-烷氧基，R.sup.4为氢，C.sub.1-C.sub.4-烷基，卤素或甲氧基，R.sup.5为氢，甲氧基或叔丁基，R.sup.6为氢，甲基，腈或C.sub.2-C.sub.10-酮基团或基团--CHR.sup.7 OR.sup.8 --CHR.sup.7 --NR.sup.9 R.sup.10，--COR.sup.11，--SR.sup.12，##STR2## 其中R.sup.7为氢或C.sub.1-C.sub.4-烷基，R.sup.8为氢，C.sub.1-C.sub.4-烷基或C.sub.1-C.sub.20-酰基或为未取代或取代为甲氧基，硝基，甲基或氯的苯甲酰基，R.sup.9和R.sup.10分别为氢，C.sub.1-C.sub.4-烷基或C.sub.1-C.sub.6-酰基或为未取代或取代为R.sup.8的苯甲酰基，或R.sup.9和R.sup.10与它们连接的氮原子一起形成饱和的五元或六元杂环基团，该基团可以以氧为第二个杂原子，R.sup.11为氢，C.sub.1-C.sub.4-烷基，--OR.sup.13或--NR.sup.14 R.sup.15，其中R.sup.13为氢，未取代或羟基取代的C.sub.1-C.sub.6-烷基，芳基或芳基烷基，其在芳基部分有未取代或取代为氯，溴，甲基，甲氧基或硝基的取代基，在芳基烷基的情况下，取代在芳基部分，R.sup.14和R.sup.15分别为氢，未取代或羟基取代的C.sub.1-C.sub.6-烷基或未取代或取代为R.sup.13的芳基烷基或芳基基团，或R.sup.14和R.sup.15与它们连接的氮原子一起形成上述定义的R.sup.9和R.sup.10的杂环基团，R.sup.12为C.sub.1-C.sub.4-烷基，以及式Ia的化合物 ##STR3## 其中R.sup.3，R.sup.4，R.sup.6和L具有上述含义，R.sup.17为氢或羟基，以及它们的生理上可耐受的盐，它们的制备过程以及制备的药物和化妆品。
• Diaryl-substituted heterocyclic compounds, drugs and cosmetics obtained
  申请人：BASF Aktiengesellschaft

  公开号：US05475017A1

  公开（公告）日：1995-12-12

  Compounds of formula I ##STR1## and compounds of formula Ia ##STR2## and their physiologically tolerated salts, processes for their preparation and drugs and cosmetics prepared therefrom.

  式I的化合物##STR1##以及式Ia的化合物##STR2##及其生理上可耐受的盐，其制备过程以及由此制备的药物和化妆品。
• Inhibitors of sphingosine kinase
  申请人：Stieber Frank

  公开号：US08907098B2

  公开（公告）日：2014-12-09

  The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, Y1, Y2, V, W, n, m and o have the meanings given herein, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、M1、M2、M3、Y1、Y2、V、W、n、m和o在此处给出的含义，并且其生理上可接受的盐、衍生物、前药、溶剂化物、互变异构体和立体异构体，包括它们在所有比例中的混合物，用于治疗受Sph激酶1抑制影响的疾病。
• DERIVES PHENYLIQUES ET LEUR UTILISATION COMME MEDICAMENT
  申请人：IPSEN PHARMA S.A.S.

  公开号：EP2102162A1

  公开（公告）日：2009-09-23